Advertisement
IRD vs PRME
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IRD is a StrongBuy and PRME is a StrongBuy.
IRD in downward trend: 10-day moving average moved below 50-day moving average on October 14, 2026
The 10-day moving average for IRD crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRD as a result. In 90 of 109 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for IRD turned negative on September 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 36 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
IRD moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for IRD entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for IRD's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRD advanced for three days, in 214 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
IRD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-22.231) is normal, around the industry mean (3.043). P/E Ratio (-2.690) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (46.083) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. IRD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PRME's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for PRME turned positive on October 06, 2026. Looking at past instances where PRME's MACD turned positive, the stock continued to rise in 30 of 35 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
PRME moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PRME crossed bullishly above the 50-day moving average on October 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +12.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRME advanced for three days, in 158 of 193 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for PRME moved out of overbought territory on October 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 16 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 40 cases where PRME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRME as a result. In 55 of 65 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
PRME broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PRME entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.333) is normal, around the industry mean (3.043). P/E Ratio (-3.495) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. PRME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IRD | PRME | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 95 | |
PRICE GROWTH RATING 1..100 | 49 | 46 | |
P/E GROWTH RATING 1..100 | 60 | 67 | |
SEASONALITY SCORE 1..100 | 32 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IRD's Valuation (7) in the null industry is in the same range as PRME (29). This means that IRD’s stock grew similarly to PRME’s over the last 12 months.
IRD's Profit vs Risk Rating (100) in the null industry is in the same range as PRME (100). This means that IRD’s stock grew similarly to PRME’s over the last 12 months.
PRME's SMR Rating (95) in the null industry is in the same range as IRD (100). This means that PRME’s stock grew similarly to IRD’s over the last 12 months.
PRME's Price Growth Rating (46) in the null industry is in the same range as IRD (49). This means that PRME’s stock grew similarly to IRD’s over the last 12 months.
IRD's P/E Growth Rating (60) in the null industry is in the same range as PRME (67). This means that IRD’s stock grew similarly to PRME’s over the last 12 months.
| IRD | PRME | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 85% |
| MACD ODDS (%) | 2 days ago 72% | 1 day ago 86% |
| TrendWeek ODDS (%) | 1 day ago 84% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 79% |
| Advances ODDS (%) | 3 days ago 83% | 4 days ago 82% |
| Declines ODDS (%) | 1 day ago 82% | 1 day ago 88% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| Aroon ODDS (%) | 1 day ago 76% | 1 day ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IRD’s FA Score shows that 1 FA rating(s) are green while PRME’s FA Score has 1 green FA rating(s).
- IRD’s FA Score: 1 green, 4 red.
- PRME’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IRD’s TA Score shows that 4 TA indicator(s) are bullish while PRME’s TA Score has 4 bullish TA indicator(s).
- IRD’s TA Score: 4 bullish, 6 bearish.
- PRME’s TA Score: 4 bullish, 6 bearish.
Price Growth
IRD (@Biotechnology) experienced а -9.64% price change this week, while PRME (@Biotechnology) price change was +5.76% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
Reported Earning Dates
IRD is expected to report earnings on Nov 11, 2026.
PRME is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IRD and
Correlation & Price change
A.I.dvisor indicates that over the last year, IRD has been loosely correlated with ARRY. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if IRD jumps, then ARRY could also see price increases.
| Ticker / NAME | Correlation To IRD | 1D Price Change % | ||
|---|---|---|---|---|
| IRD | 100% | -9.16% | ||
| ARRY - IRD | 35% Loosely correlated | -3.33% | ||
| PRME - IRD | 34% Loosely correlated | -1.61% | ||
| CABA - IRD | 31% Poorly correlated | -3.29% | ||
| DMAC - IRD | 31% Poorly correlated | +1.04% | ||
| NGNE - IRD | 31% Poorly correlated | -3.01% | ||
More | ||||
PRME and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To PRME | 1D Price Change % | ||
|---|---|---|---|---|
| PRME | 100% | -1.61% | ||
| CRSP - PRME | 66% Loosely correlated | -1.20% | ||
| BEAM - PRME | 64% Loosely correlated | -2.08% | ||
| RXRX - PRME | 62% Loosely correlated | +3.35% | ||
| EDIT - PRME | 62% Loosely correlated | -3.61% | ||
| RCKT - PRME | 55% Loosely correlated | -0.87% | ||
More | ||||